<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: common stock could decline", fill: "#8b0000"},
{source: "2: common stock could decline", target: "2: could lose", fill: "#8b0000"},
{source: "2: could lose", target: "2: investment", fill: "#8b0000"},
{source: "2: common stock could decline", target: "8: governmental", fill: "#d3d3d3"},
{source: "8: governmental", target: "8: successful bidder on", fill: "#d3d3d3"},
{source: "8: successful bidder on", target: "8: negotiate terms", fill: "#d3d3d3"},
{source: "8: negotiate terms", target: "8: connection with", fill: "#d3d3d3"},
{source: "8: connection with", target: "8: us which could adversely affect", fill: "#d3d3d3"},
{source: "8: us which could adversely affect", target: "8: operations", fill: "#d3d3d3"},
{source: "8: operations", target: "8: financial condition", fill: "#d3d3d3"},
{source: "8: governmental", target: "13: agreement", fill: "#a8516e"},
{source: "13: agreement", target: "13: December ", fill: "#a8516e"},
{source: "13: December ", target: "13: scrapie genotyping", fill: "#a8516e"},
{source: "13: scrapie genotyping", target: "13: which would", fill: "#a8516e"},
{source: "13: which would", target: "13: impact on", fill: "#a8516e"},
{source: "13: impact on", target: "13: financial condition", fill: "#a8516e"},
{source: "13: agreement", target: "37: international sales which", fill: "#faf0be"},
{source: "37: international sales which", target: "37: inherent risks", fill: "#faf0be"},
{source: "37: inherent risks", target: "37: difficulties", fill: "#faf0be"},
{source: "37: difficulties", target: "37: collecting accounts receivable", fill: "#faf0be"},
{source: "37: collecting accounts receivable", target: "37: potentially", fill: "#faf0be"},
{source: "37: potentially", target: "37: increased costs associated with", fill: "#faf0be"},
{source: "37: increased costs associated with", target: "37: regulatory requirements", fill: "#faf0be"},
{source: "37: regulatory requirements", target: "37: enforcement", fill: "#faf0be"},
{source: "37: enforcement", target: "37: contractual obligations", fill: "#faf0be"},
{source: "37: contractual obligations", target: "37: intellectual property rights", fill: "#faf0be"},
{source: "37: international sales which", target: "45: If ", fill: "#79443b"},
{source: "45: If ", target: "45: Contents ", fill: "#79443b"},
{source: "45: Contents ", target: "45: reach cash flow self sufficiency", fill: "#79443b"},
{source: "45: reach cash flow self sufficiency", target: "45: raise additional", fill: "#79443b"},
{source: "45: raise additional", target: "45: equity convertible debt", fill: "#79443b"},
{source: "45: equity convertible debt", target: "45: further review", fill: "#79443b"},
{source: "45: further review", target: "45: existing operations", fill: "#79443b"},
{source: "45: existing operations", target: "45: new measures", fill: "#79443b"},
{source: "45: new measures", target: "45: cost reduction such as further consolidation", fill: "#79443b"},
{source: "45: cost reduction such as further consolidation", target: "45: operational facilities andor reductions", fill: "#79443b"},
{source: "45: If ", target: "48: common stock", fill: "#da9100"},
{source: "48: common stock", target: "48: delisted from", fill: "#da9100"},
{source: "48: delisted from", target: "48: The Nasdaq National Market ", fill: "#da9100"},
{source: "48: The Nasdaq National Market ", target: "48: stock such delisting would", fill: "#da9100"},
{source: "48: stock such delisting would", target: "48: market would continue", fill: "#da9100"},
{source: "48: common stock", target: "58: acquisition", fill: "#9932cc"},
{source: "58: acquisition", target: "58: operations", fill: "#9932cc"},
{source: "58: operations", target: "58: technologies into", fill: "#9932cc"},
{source: "58: technologies into", target: "58: organization effectively", fill: "#9932cc"},
{source: "58: organization effectively", target: "58: motivate personnel", fill: "#9932cc"},
{source: "58: motivate personnel", target: "58: merged businesses", fill: "#9932cc"},
{source: "58: acquisition", target: "62: commercializing", fill: "#ff0090"},
{source: "62: commercializing", target: "62: technologies", fill: "#ff0090"},
{source: "62: commercializing", target: "START_HERE", fill: "#ff0090"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Home Improvement Retail</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Accuse</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December">December</a></td>
      <td>December is the twelfth and the final month of the year in the Julian and Gregorian calendars. It is also the last of seven months to have a length of 31 days.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_17">December 17</a></td>
      <td>December 17 is the 351st day of the year (352nd in leap years) in the Gregorian calendar;  14 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n497 BC – The first Saturnalia festival was celebrated in ancient Rome.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_10">December 10</a></td>
      <td>December 10 is the 344th day of the year (345th in leap years) in the Gregorian calendar;  21 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n1317 – The "Nyköping Banquet": King Birger of Sweden treacherously seizes his two brothers Valdemar, Duke of Finland and Eric, Duke of Södermanland, who were subsequently starved to death in the dungeon of Nyköping Castle.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_1924_German_federal_election">December 1924 German federal election</a></td>
      <td>Federal elections were held in Germany on 7 December 1924, the second that year after the Reichstag had been dissolved on 20 October. The Social Democratic Party remained the largest party in the Reichstag, receiving an increased share of the vote and winning 131 of the 493 seats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_1">December 1</a></td>
      <td>December is the twelfth and the final month of the year in the Julian and Gregorian calendars. It is also the last of seven months to have a length of 31 days.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_18">December 18</a></td>
      <td>December 11 is the 345th day of the year (346th in leap years) in the Gregorian calendar;  20 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n220 – Emperor Xian of Han is forced to abdicate the throne by Cao Cao's son Cao Pi, ending the Han dynasty.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_26">December 26</a></td>
      <td>December 15 is the 349th day of the year (350th in leap years) in the Gregorian calendar;  16 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n533 – Vandalic War: Byzantine general Belisarius defeats the Vandals, commanded by King Gelimer, at the Battle of Tricamarum.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_31">December 31</a></td>
      <td>December 3 is the 337th day of the year (338th in leap years) in the Gregorian calendar;  28 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n915 – Pope John X crowns Berengar I of Italy as Holy Roman Emperor (probable date).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_8">December 8</a></td>
      <td>December 3 is the 337th day of the year (338th in leap years) in the Gregorian calendar;  28 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n915 – Pope John X crowns Berengar I of Italy as Holy Roman Emperor (probable date).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_property">Intellectual property</a></td>
      <td>Intellectual property (IP) is a category of property that includes intangible creations of the human intellect. There are many types of intellectual property, and some countries recognize more than others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Convertible_bond">Convertible bond</a></td>
      <td>In finance, a convertible bond or  convertible note or convertible debt (or a convertible debenture if it has a maturity of greater than 10 years) is a type of bond that the holder can convert into a specified number of shares of common stock in the issuing company or cash of equal value.  It is a hybrid security with debt- and equity-like features.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preferred_stock">Preferred stock</a></td>
      <td>Preferred stock (also called preferred shares, preference shares, or simply preferreds) is a component of share capital that may have any combination of features not possessed by common stock, including properties of both an equity and a debt instrument, and is generally considered a hybrid instrument. Preferred stocks are senior (i.e., higher ranking) to common stock but subordinate to bonds in terms of claim (or rights to their share of the assets of the company, given that such assets are payable to the returnee stock bond) and may have priority over common stock (ordinary shares) in the payment of dividends and upon liquidation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock_dividend">Common stock dividend</a></td>
      <td>A common stock dividend is the dividend paid to common stock owners from the profits of the company.  Like other dividends, the payout is in the form of either cash or stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Treasury_stock">Treasury stock</a></td>
      <td>A treasury stock or reacquired stock is stock which is bought back by the issuing company, reducing the amount of outstanding stock on the open market ("open market" including insiders' holdings). \nStock repurchases are used as a tax efficient method to put cash into shareholders' hands, rather than paying dividends, in jurisdictions that treat capital gains more favorably.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/HCL_Technologies">HCL Technologies</a></td>
      <td>HCL Technologies (Hindustan Computers Limited) is an Indian multinational information technology (IT) services and consulting company headquartered in Noida. It is a subsidiary of HCL Enterprise.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Raytheon_Technologies">Raytheon Technologies</a></td>
      <td>Raytheon Technologies Corporation is an American multinational aerospace and defense conglomerate headquartered in Waltham, Massachusetts. It is one of the largest aerospace, intelligence services providers, and defense manufacturers in the world by revenue and market capitalization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renaissance_Technologies">Renaissance Technologies</a></td>
      <td>Renaissance Technologies LLC, also known as RenTech or RenTec, is an American hedge fund based in East Setauket, New York, on Long Island, which specializes in systematic trading using quantitative models derived from mathematical and statistical analysis. Their signature Medallion fund is famed for the best record in investing history.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emerging_technologies">Emerging technologies</a></td>
      <td>Emerging technologies are technologies whose development, practical applications, or both are still largely unrealized, such that they are figuratively emerging into prominence from a background of nonexistence or obscurity. These technologies are generally new but also include older technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Palantir_Technologies">Palantir Technologies</a></td>
      <td>Palantir Technologies is a public American software company that specializes in big data analytics. Headquartered in Denver, Colorado, it was founded by Peter Thiel, Nathan Gettings, Joe Lonsdale, Stephen Cohen, and Alex Karp in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lumen_Technologies">Lumen Technologies</a></td>
      <td>Lumen Technologies, Inc. (formerly CenturyLink) is an American \ntelecommunications company headquartered in Monroe, Louisiana, that offers communications, network services, security, cloud solutions, voice, and managed services.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ORCHID CELLMARK INC      Item 1A RISK FACTORS          If any of the matters included in the <font color="blue">following risks</font> were to occur, our     business,  financial  condition,  results of <font color="blue">operations</font>, cash flows or     <font color="blue">prospects could</font> be <font color="blue">materially <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font></font></td>
    </tr>
    <tr>
      <td>In such case, the value of     our  <font color="blue"><font color="blue">common stock</font> could decline</font> and you <font color="blue">could lose</font> all or part of your     <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>Risks Related to Our Business          If we fail to maintain the <font color="blue">service contracts</font> we have <font color="blue">with various</font> state and     <font color="blue"><font color="blue">governmental</font> agencies</font> or fail to <font color="blue"><font color="blue">enter into</font> <font color="blue">additional</font> contracts</font>, we would     lose a <font color="blue"><font color="blue">significant</font> source</font> of revenues</td>
    </tr>
    <tr>
      <td>We currently derive <font color="blue">approximately</font> 98prca of our <font color="blue">revenues from</font> the forensic,     family  <font color="blue">relationship</font> and animal and <font color="blue"><font color="blue">agricultural testing</font> fields</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>services are heavily dependent upon contracts <font color="blue">with various</font> <font color="blue">governmental</font>     agencies, which are <font color="blue">typically open</font> to bid and usually have a <font color="blue">term from one</font>     to <font color="blue">three years</font></td>
    </tr>
    <tr>
      <td>The process and criteria for these awards are typically     complex  and highly competitive, particularly with respect to price of     services  offered</td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we  have not <font color="blue">previously been debarred</font> or     disqualified  for  breach  or non-performance of any contract, if such     <font color="blue">debarment</font> or <font color="blue">disqualification</font> were to occur we may not be <font color="blue">awarded future</font>     state or <font color="blue">government contracts</font></td>
    </tr>
    <tr>
      <td>We may not be able to maintain any of our     existing  <font color="blue">governmental</font>  contracts  or  be the <font color="blue">successful bidder on</font> any     <font color="blue">additional</font> <font color="blue">governmental</font> contracts which may become available in the future,     or <font color="blue">negotiate terms</font> acceptable to us in <font color="blue">connection with</font> any <font color="blue">governmental</font>     contract  awarded  to  us, which <font color="blue">could <font color="blue"><font color="blue">adversely</font> affect</font></font> our results of     <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We currently receive a <font color="blue"><font color="blue">significant</font> percentage</font> of our annual gross revenue     through <font color="blue">relationship</font>s with two customers and <font color="blue"><font color="blue">agreement</font>s with</font> these customers     <font color="blue">may terminate</font></td>
    </tr>
    <tr>
      <td>In August of 2001, we entered into a three-year <font color="blue">agreement</font> with DEFRA to     provide  <font color="blue">genotyping</font>  on  sheep  in order to test the animals for their     <font color="blue">susceptibility</font> or resistance to scrapie, which <font color="blue">agreement</font> was renewed <font color="blue">in June     </font>of 2004 for two <font color="blue">additional</font> years</td>
    </tr>
    <tr>
      <td>These services were <font color="blue">provided under</font> an     initiative called the <font color="blue">National Scrapie Plan </font>to provide <font color="blue">genotyping</font> services     in  the  hopes  of  aiding British farmers to breed <font color="blue">sheep with reduced</font>     <font color="blue">susceptibility</font> to scrapie</td>
    </tr>
    <tr>
      <td>Under the <font color="blue">agreement</font>, we received income during     2005 that was <font color="blue">approximately</font> 8prca of our total annual revenues</td>
    </tr>
    <tr>
      <td>This <font color="blue">agreement</font>     expires in <font color="blue">December </font>of 2006 and if we cannot renew this <font color="blue">agreement</font> with     DEFRA, we would lose our scrapie <font color="blue">genotyping</font> business, <font color="blue">which would</font> have a     material <font color="blue">impact on</font> the <font color="blue">financial condition</font> of our business</td>
    </tr>
    <tr>
      <td>We also signed a five-year <font color="blue">agreement</font> in July of 2002 with FAL, an agency     through which we perform forensic <font color="blue">testing services</font> for multiple police     forces <font color="blue">throughout</font> the UK It is by virtue of our <font color="blue">relationship</font> with FAL that     we have been able to increase our revenues <font color="blue">based on</font> <font color="blue">forensic testing</font> such     that the income we received was <font color="blue">approximately</font> 29prca of our gross revenues for     the <font color="blue">fiscal year</font> ended <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>In 2005, FAL was acquired by LGC, a     provider  of analytical and <font color="blue">diagnostic</font> services, including DNA testing     services, and to that extent is in a position to compete for the business we     <font color="blue">currently conduct</font> for FAL If our <font color="blue">agreement</font> with FAL is terminated and we     are unable to implement plans to <font color="blue">enable us</font> to <font color="blue">directly provide</font> our services     to  UK <font color="blue">police forces</font>, including having in place in a <font color="blue">timely manner</font> the     <font color="blue">necessary personnel</font> and <font color="blue">infrastructure</font>, or are <font color="blue">unsuccessful</font> in securing a     sufficient number of <font color="blue">agreement</font>s directly with UK <font color="blue">police forces</font>, our business     would be <font color="blue">materially <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font></font></td>
    </tr>
    <tr>
      <td>Together, these two <font color="blue">agreement</font>s constituted 78prca of <font color="blue">international revenues</font> and     37prca of our <font color="blue">total revenues</font> for the <font color="blue">fiscal year</font> ended <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot guarantee</font> the receipt of <font color="blue">revenue from</font> our <font color="blue">government contracts</font></td>
    </tr>
    <tr>
      <td>We  <font color="blue">regularly compete</font> in an <font color="blue">open bid forum</font> in order to secure or renew     contracts <font color="blue">with various</font> law <font color="blue">enforcement</font> and <font color="blue"><font color="blue">governmental</font> agencies</font> for the     provision of DNA-based <font color="blue">testing services</font></td>
    </tr>
    <tr>
      <td>While many times a contract award     may have limits that may be <font color="blue">paid out under</font> the contract (as allowed by state     or other approved                                           13     ______________________________________________________________________    [37]Table of <font color="blue">Contents       </font>funding), we are not <font color="blue">always able</font> to rely on a fixed amount of <font color="blue">revenue based</font>     on  services  <font color="blue">provided under</font> the contract</td>
    </tr>
    <tr>
      <td>For example, there may be a     <font color="blue">regulatory</font> or other <font color="blue">administrative basis beyond</font> our control for which we do     not receive the anticipated number of samples to be <font color="blue">tested under</font> a contract,     which may have an <font color="blue">adverse outcome on services billed</font> or revenue received     during  a  <font color="blue">given fiscal period</font></td>
    </tr>
    <tr>
      <td>Also, many contracts with <font color="blue">governmental</font>     <font color="blue">agencies allow</font> for the agency to terminate a <font color="blue">contract at</font> any time if funding     is not available to pay for our services</td>
    </tr>
    <tr>
      <td>Our failure to <font color="blue">comply with applicable government</font> and <font color="blue">industry regulations</font> or     to maintain <font color="blue"><font color="blue">accreditation</font>s may affect</font> our ability to develop, produce or     market our <font color="blue">potential products</font> and services and <font color="blue">may <font color="blue"><font color="blue">adversely</font> affect</font></font> our     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>All of our <font color="blue">laboratories</font> maintain applicable industry <font color="blue">accreditation</font>s for     <font color="blue">paternity</font> and <font color="blue">forensic testing</font> both in the US and the UK, and voluntary     <font color="blue">accreditation</font>  by  the  <font color="blue">New York State Department of Health </font>and by the     <font color="blue">Standards Council of Canada</font></td>
    </tr>
    <tr>
      <td>In addition, our UK <font color="blue">laboratory must</font> maintain     ISO 17025 <font color="blue">accreditation</font> in order to continue to <font color="blue">provide <font color="blue">forensic testing</font></font>     services</td>
    </tr>
    <tr>
      <td>We  cannot  assure you that we will be able to maintain our     <font color="blue">accreditation</font>s</td>
    </tr>
    <tr>
      <td>The loss of our <font color="blue">accreditation</font>s <font color="blue">could <font color="blue"><font color="blue">adversely</font> affect</font></font> our     <font color="blue">existing contracts which</font>, in many cases, require that we maintain these     <font color="blue">accreditation</font>s, and <font color="blue">could <font color="blue"><font color="blue">adversely</font> affect</font></font> our ability to <font color="blue"><font color="blue">enter into</font> new</font>     contracts</td>
    </tr>
    <tr>
      <td>As a result, our revenues could be eliminated or <font color="blue"><font color="blue">significant</font>ly</font>     reduced</td>
    </tr>
    <tr>
      <td>Our <font color="blue">development</font> and <font color="blue">testing activities also involve</font> the <font color="blue">controlled use</font> of     <font color="blue">hazardous materials</font></td>
    </tr>
    <tr>
      <td>We are subject to laws and <font color="blue">regulations governing</font> the     use, storage, handling and disposal of <font color="blue">such materials</font> and <font color="blue">certain waste</font>     products, as well as the conveyance, processing and storage of biological     specimens</td>
    </tr>
    <tr>
      <td>If we were in violation of any laws or <font color="blue">regulations pertaining</font> to     the handling or use of <font color="blue">hazardous materials</font>, the <font color="blue">remediation costs could</font> be     high and could have an adverse effect on our business and financial results</td>
    </tr>
    <tr>
      <td>We  currently  <font color="blue">rely primarily on</font> a <font color="blue">single supplier</font> for the majority of     reagents  and  other <font color="blue">components</font> for the performance of our DNA testing     services</td>
    </tr>
    <tr>
      <td>We currently have a purchase <font color="blue">agreement</font> with one supplier through which we     purchase the majority of reagents and other <font color="blue">components</font> for use in our DNA     testing  services</td>
    </tr>
    <tr>
      <td>Through this purchase <font color="blue">agreement</font> we have negotiated     favorable <font color="blue">discounts</font> for the purchase of these <font color="blue">products <font color="blue">based on</font></font> the volume     of what we purchase</td>
    </tr>
    <tr>
      <td>In the event our current supplier was to experience a     major  supply problem, we do have the ability to purchase reagents and     <font color="blue">components</font> from other suppliers</td>
    </tr>
    <tr>
      <td>However, if we had to switch to a <font color="blue">different</font>     supplier  or <font color="blue">multiple suppliers</font>, we may be required to also change the     <font color="blue">instruments on which</font> we perform DNA <font color="blue">testing services</font>, <font color="blue">which could</font> require     <font color="blue">significant</font> capital <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td><font color="blue">International </font>sales are subject to <font color="blue">increased costs</font> and other risks, which     <font color="blue">could affect</font> our revenues</td>
    </tr>
    <tr>
      <td>Our business includes <font color="blue">international sales which</font> are subject to certain     <font color="blue">inherent risks</font>, including <font color="blue">difficulties</font> in <font color="blue">collecting accounts receivable</font>,     <font color="blue">potentially</font>  longer  payment  cycles,  <font color="blue">increased costs</font> <font color="blue">associated with</font>     maintaining international marketing efforts, currency <font color="blue">fluctuations</font> as they     impact reported results, changes in <font color="blue">regulatory</font> <font color="blue">requirements</font> and <font color="blue">difficulties</font>     in <font color="blue">enforcement</font> of <font color="blue"><font color="blue">contractual</font> obligations</font> and <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font></td>
    </tr>
    <tr>
      <td>During 2005, we derived 47prca of our <font color="blue">revenues from</font> international sales</td>
    </tr>
    <tr>
      <td>We had an <font color="blue">accumulated deficit</font> of dlra306 million as of <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>If we     fail to <font color="blue">reach profitability</font> and need to acquire <font color="blue">additional</font> capital to fund     our current and future operating plans or obtain it <font color="blue">on unfavorable terms</font>,     then we may have to take further cost-cutting measures</td>
    </tr>
    <tr>
      <td>We have <font color="blue">expended <font color="blue">significant</font> resources</font> developing our <font color="blue">facilities</font> and funding     <font color="blue">commercialization activities</font></td>
    </tr>
    <tr>
      <td>As a result, we have incurred <font color="blue">significant</font>     losses  to date</td>
    </tr>
    <tr>
      <td>We had net losses of <font color="blue">approximately</font> dlra9dtta4 million, dlra8dtta8     million and dlra23dtta6 million for the years ended <font color="blue">December </font>31, 2005, 2004 and     2003, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>We anticipate that our <font color="blue">existing cash on hand will</font> be     sufficient to fund our <font color="blue">operations</font> at least through the <font color="blue">next twelve months</font></td>
    </tr>
    <tr>
      <td><font color="blue">If                                           </font>14     ______________________________________________________________________    [38]Table of <font color="blue">Contents       </font>we fail to <font color="blue">reach cash flow self sufficiency</font>, we may need to raise <font color="blue">additional</font>     funds  through  the  sale of equity, convertible debt or equity-linked     securities or we may have to <font color="blue">further review</font> our existing <font color="blue">operations</font> to     determine <font color="blue">new measures</font> of cost reduction, such as further consolidation of     operational <font color="blue">facilities</font> and/or reductions in staff</td>
    </tr>
    <tr>
      <td>As a result of our failure to file this <font color="blue">Annual Report </font>on Form 10-K by its     filing  deadline,  we are not eligible to register our <font color="blue">securities on</font> a     <font color="blue">registration</font>  statement  on  Form S-3</td>
    </tr>
    <tr>
      <td>Therefore, our ability to raise     <font color="blue">additional</font> capital in the <font color="blue"><font color="blue">public market</font>s may</font> be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font> because     <font color="blue">registering</font> our <font color="blue">securities on</font> other forms, including <font color="blue">registration</font> statements     on Form S-1, is time consuming and costly</td>
    </tr>
    <tr>
      <td>In addition, if our <font color="blue">common stock</font>     were <font color="blue">delisted from</font> <font color="blue"><font color="blue">The Nasdaq National Market</font> </font>stock, such delisting would     impair the liquidity of our <font color="blue">common stock</font> and there is no assurance that a     <font color="blue"><font color="blue">market would</font> continue</font> to exist for our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our potential to raise     future capital through the sale of our <font color="blue">equity securities would</font> be limited,     <font color="blue">which could</font> have a material adverse effect on our future business prospects</td>
    </tr>
    <tr>
      <td>We have determined that we have material <font color="blue">weaknesses</font> in our <font color="blue">internal control</font>     <font color="blue">over financial</font> reporting</td>
    </tr>
    <tr>
      <td><font color="blue">Under Section </font>302 of the Sarbanes-Oxley Act of 2002, we are required to     evaluate  and determine the <font color="blue"><font color="blue">effective</font>ness</font> of our <font color="blue">internal control</font> over     financial reporting</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we did not maintain <font color="blue">effective</font>     <font color="blue">internal control</font> over the <font color="blue">application</font> of <font color="blue">generally accepted accounting</font>     principles, or GAAP, related to the financial reporting process, and we     determined  that we experienced two control deficiencies, one of which     resulted  in  an <font color="blue">adjustment</font> being required to restate our <font color="blue">consolidated</font>     <font color="blue">financial statements</font> for them to be in <font color="blue">compliance with</font> GAAP Accordingly,     <font color="blue">management</font>  has  determined that these <font color="blue">control deficiencies constitute</font>     material <font color="blue">weaknesses</font></td>
    </tr>
    <tr>
      <td>Because of these material <font color="blue">weaknesses</font>, our <font color="blue">management</font>     concluded that, as of <font color="blue">December </font>31, 2005, we did not maintain <font color="blue">effective</font>     <font color="blue">internal control</font> <font color="blue">over financial</font> reporting</td>
    </tr>
    <tr>
      <td>If we are not successful in     <font color="blue">remediating</font> the material <font color="blue">weaknesses</font>, or if we determine in <font color="blue">future fiscal</font>     periods that we have <font color="blue">additional</font> material <font color="blue">weaknesses</font> in our <font color="blue">internal control</font>     <font color="blue">over financial</font> reporting, the <font color="blue">reliability</font> of our financial reports may be     impacted</td>
    </tr>
    <tr>
      <td>Future  <font color="blue"><font color="blue">acquisition</font>s</font>  or <font color="blue">mergers could disrupt</font> our ongoing <font color="blue">operations</font>,     increase our expenses and <font color="blue"><font color="blue">adversely</font> affect</font> our revenues</td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we  have  no  <font color="blue">commitments</font>  or <font color="blue"><font color="blue">agreement</font>s with</font> respect to any     <font color="blue"><font color="blue">acquisition</font>s</font> or <font color="blue">mergers at present</font>, we anticipate that a portion of our     future  <font color="blue">growth may</font> be accomplished <font color="blue">either by</font> acquiring or <font color="blue">merging with</font>     <font color="blue">existing businesses</font></td>
    </tr>
    <tr>
      <td>Factors that will affect the success of any potential     <font color="blue">acquisition</font> or merger to be made by us include our ability to integrate     acquired  personnel,  <font color="blue">operations</font>,  products  and <font color="blue"><font color="blue">technologies</font> into</font> our     organization <font color="blue">effective</font>ly, to <font color="blue">motivate personnel</font> and to retain customers of     acquired or <font color="blue">merged businesses</font></td>
    </tr>
    <tr>
      <td>We may not be able to identify suitable     <font color="blue">acquisition</font> or <font color="blue">merger opportunities</font>, obtain <font color="blue">necessary financing</font> for an     <font color="blue">acquisition</font> on acceptable terms or <font color="blue"><font color="blue">successfully</font> integrate</font> acquired personnel     and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>While we have not experienced material <font color="blue">disruption</font> to our     ongoing business or <font color="blue">distraction</font> to our <font color="blue">management</font> and <font color="blue">employees as</font> a result     of past <font color="blue"><font color="blue">acquisition</font>s</font>, we may experience such <font color="blue">disruption</font>s or <font color="blue">distraction</font>s in     the future</td>
    </tr>
    <tr>
      <td>Our <font color="blue">improvement</font> of <font color="blue">existing <font color="blue">technologies</font></font> and our ability to capture and     develop <font color="blue">future <font color="blue">technologies</font></font> to be utilized in our <font color="blue"><font color="blue">service offerings</font> may</font> not     be <font color="blue">commercially successful</font>, which <font color="blue">could <font color="blue"><font color="blue">adversely</font> affect</font></font> our revenues</td>
    </tr>
    <tr>
      <td>We are currently developing and <font color="blue">commercializing</font> a limited number of services     based  on our <font color="blue">technologies</font> in DNA testing of humans and animals</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">services involve uses</font> of products, software and <font color="blue">technologies</font> that require     <font color="blue">validation</font> for commercial <font color="blue">application</font>, and we <font color="blue">cannot assure</font> you that we or     our <font color="blue">customers will</font> be able to recognize a cost-<font color="blue">effective</font>, commercial benefit     in using our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>In addition, any assays we develop utilizing SNP     analysis <font color="blue">technology</font> may not be useful in assisting in <font color="blue">food safety testing</font></td>
    </tr>
    <tr>
      <td>Only a limited number of companies have developed or <font color="blue"><font color="blue">commercialize</font>d</font> products     <font color="blue">based on</font> utilizing SNP <font color="blue">technology</font> to date</td>
    </tr>
    <tr>
      <td>Accordingly, even if we or our     customers  are successful in developing <font color="blue">effective</font> assays utilizing SNP     <font color="blue">technology</font>, we cannot                                           15     ______________________________________________________________________    [39]Table of <font color="blue">Contents       </font>assure you that these <font color="blue">discoveries will lead</font> to <font color="blue">commercially successful</font>     service  offerings</td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">successfully</font> develop our SNP scoring     <font color="blue">technologies</font> or any products and services <font color="blue">based on</font> such <font color="blue">technologies</font>, we may     not achieve a <font color="blue">competitive position</font> in the market</td>
    </tr>
    <tr>
      <td>We may be unable to hire an adequate number of DNA analysts or <font color="blue">successfully</font>     apply new <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Our growth     and future operating results <font color="blue">will also depend</font>, in part, upon our ability to     apply new <font color="blue">technologies</font> to automate and improve our DNA <font color="blue">testing services</font> to     take advantage of new <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that our     <font color="blue">development</font> efforts will result in any <font color="blue">additional</font> commercially viable or     successful  <font color="blue">improvement</font>s or <font color="blue">efficiencies</font> to our <font color="blue">testing processes</font></td>
    </tr>
    <tr>
      <td>Any     potential  <font color="blue">improvement</font>s to the <font color="blue">testing process may</font> require substantial     <font color="blue">additional</font>  <font color="blue">investment</font>  and  possibly  <font color="blue">regulatory</font>  approvals, prior to     <font color="blue">implementation</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to <font color="blue">recruit trained</font> DNA analysts, to develop     <font color="blue">improvement</font>s to our <font color="blue">testing processes</font>, to increase <font color="blue">efficiencies</font>, or to     achieve <font color="blue">market acceptance</font> of such <font color="blue">improvement</font>s could have a material adverse     effect on our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future sales</font> and <font color="blue">marketing efforts may</font> not be successful in achieving     our expected <font color="blue">revenue growth</font></td>
    </tr>
    <tr>
      <td>We plan to continue to market our products and services to <font color="blue">governments</font>,     <font color="blue">commercial companies</font> and <font color="blue">private <font color="blue">individuals</font></font></td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">successfully</font>     obtain  new  business,  and where <font color="blue">appropriate</font>, <font color="blue">enter into</font> and maintain     <font color="blue"><font color="blue">agreement</font>s with</font> our customers, depends in part on the quality and pricing of     our products and services</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">successfully</font> implement our     marketing plans, fail to maintain or enhance the quality of our products and     services, or fail to <font color="blue">offer attractive pricing</font> for our products and services,     our expected <font color="blue">revenue growth</font> and <font color="blue">financial condition</font> could be <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>We have <font color="blue">adequate sales</font> and <font color="blue">marketing resources</font>, but if our <font color="blue">resources become</font>     limited, we may not achieve our expected <font color="blue">revenue growth</font></td>
    </tr>
    <tr>
      <td>We believe that we currently have <font color="blue">adequate resources</font> in marketing and sales,     but are subject to the <font color="blue">possibility</font> that our <font color="blue"><font color="blue">competitors</font> may recruit</font> our     employees</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we had 12 key marketing and sales     employees,  none  of whom have <font color="blue">employment contracts with us</font></td>
    </tr>
    <tr>
      <td>We do not     maintain <font color="blue">key man life insurance policies</font> for any of these <font color="blue">individuals</font></td>
    </tr>
    <tr>
      <td>Our     sales  and  marketing  resources  are  used  to market our services to     <font color="blue">governments</font>, <font color="blue">commercial companies</font> and <font color="blue">private <font color="blue">individuals</font></font></td>
    </tr>
    <tr>
      <td>If we do not have     <font color="blue">adequate sales</font> and <font color="blue">marketing resources</font>, our expected <font color="blue">revenue growth</font> and     <font color="blue">financial condition</font> could be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font></td>
    </tr>
    <tr>
      <td>We may be held liable for any <font color="blue">inaccuracies</font> <font color="blue">associated with</font> our services,     which may require us to <font color="blue">defend ourselves</font> in <font color="blue">costly <font color="blue">litigation</font></font></td>
    </tr>
    <tr>
      <td>We provide forensic, family <font color="blue">relationship</font> and animal and <font color="blue">agriculture testing</font>     services</td>
    </tr>
    <tr>
      <td>Claims may be <font color="blue">brought against us</font> for incorrect <font color="blue">identification</font> of     family <font color="blue">relationship</font>s or other <font color="blue">inaccuracies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>of these claims in     most cases is <font color="blue">covered by</font> our existing insurance policies</td>
    </tr>
    <tr>
      <td>However, we could     expend <font color="blue">significant</font> funds during any <font color="blue">litigation</font> proceeding <font color="blue">brought against us</font>     and  <font color="blue">litigation</font> can be a <font color="blue">distraction</font> to <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>If a court were to     require us to pay damages to a plaintiff, if not <font color="blue">covered by</font> our existing     insurance, the amount of such damages could <font color="blue"><font color="blue">significant</font>ly</font> harm our financial     condition, and even if insured, damages could exceed our <font color="blue">insurance policy</font>     <font color="blue">coverage limits</font></td>
    </tr>
    <tr>
      <td>We currently maintain <font color="blue">product liability insurance with</font> a     maximum  coverage  <font color="blue">limitation</font>  of  dlra5  million  and <font color="blue">general laboratory</font>     <font color="blue">professional liability insurance with</font> a maximum coverage <font color="blue">limitation</font> of dlra10     million</td>
    </tr>
    <tr>
      <td>We have been named a <font color="blue">defendant</font> in a number of <font color="blue">minor suits</font> relating     to our DNA <font color="blue">testing services</font>, including claims of incorrect results</td>
    </tr>
    <tr>
      <td>16     ______________________________________________________________________    [40]Table of <font color="blue">Contents       </font>Our ability to <font color="blue">provide services may</font> be <font color="blue">seriously impaired by</font> the occurrence     of a <font color="blue">natural disaster affecting</font> any one or more of our <font color="blue">laboratories</font></td>
    </tr>
    <tr>
      <td>Should we experience the occurrence of a <font color="blue">natural disaster affecting</font> any one     or more of our <font color="blue">laboratories</font> such that we would be unable to continue to     <font color="blue">provide services out</font> of a <font color="blue">particular facility</font> for an <font color="blue">extended period</font> of     time, and we were not able to scale up <font color="blue">operations</font> at our other <font color="blue">facilities</font> in     order to continue to <font color="blue">provide <font color="blue">such services</font></font>, we would be at risk of losing     <font color="blue">significant</font> <font color="blue">contractual</font> <font color="blue">revenue from</font> <font color="blue"><font color="blue">governmental</font> agencies</font> since many of our     <font color="blue">governmental</font> agency contracts allow for the agency to terminate the contract     early  if  we <font color="blue">became unable</font> to continue to render <font color="blue">such services</font> for an     <font color="blue">extended period</font> of time, usually 90 days or more</td>
    </tr>
    <tr>
      <td>However, we have multiple     <font color="blue">facilities</font>, and may be able to shift <font color="blue">operations</font> from one facility to another     in the event of a natural disaster, thereby mitigating the <font color="blue">effects thereof</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we carry insurance for recovery in the instance of a natural     disaster, the limits of this insurance are dlra70 million, and it is possible     that our <font color="blue">coverage will</font> not be the same in all locations or that a loss in     such an <font color="blue">instance could exceed</font> our ability to <font color="blue">recover such costs</font></td>
    </tr>
    <tr>
      <td>Our  success  will  depend  partly  on  our ability to operate without     <font color="blue">misappropriating</font> the <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font> of others</td>
    </tr>
    <tr>
      <td>We may be sued for infringing, or may initiate <font color="blue">litigation</font> to determine that     we  are not infringing, on the <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font> of others</td>
    </tr>
    <tr>
      <td><font color="blue">Intellectual </font>property <font color="blue">litigation</font> is costly, and <font color="blue">could <font color="blue"><font color="blue">adversely</font> affect</font></font> our     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we do not prevail in any <font color="blue"><font color="blue">intellectual</font> property</font>     <font color="blue">litigation</font>, in addition to any damages we might have to pay, we could be     required to stop the <font color="blue">infringing activity</font>, or obtain a license to or design     around the <font color="blue"><font color="blue">intellectual</font> property</font> in question</td>
    </tr>
    <tr>
      <td>If we are unable to obtain a     required  license  on  acceptable  terms,  or  are  unable to practice     non-infringing <font color="blue">technologies</font> or processes, we may be unable to sell some of     our products and services, <font color="blue">which would</font> result in <font color="blue">reduced revenues</font></td>
    </tr>
    <tr>
      <td>We are     named a <font color="blue">defendant</font> in a patent <font color="blue">litigation</font> matter</td>
    </tr>
    <tr>
      <td>However, we believe we have     the right to practice such <font color="blue">technology</font> by virtue of a third-party <font color="blue">agreement</font>,     and we are actively engaged in defending this <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>Other than the     foregoing, we are not aware that we are <font color="blue">misappropriating</font> the <font color="blue">intellectual</font>     <font color="blue">property rights</font> of others</td>
    </tr>
    <tr>
      <td>If we cannot <font color="blue"><font color="blue">enter into</font> new</font> <font color="blue">development</font> or licensing <font color="blue">agreement</font>s, we may be     unable to <font color="blue">further enhance</font> our <font color="blue">service offerings</font></td>
    </tr>
    <tr>
      <td>Our strategy for developing and <font color="blue">commercializing</font> <font color="blue">technologies</font> and services     <font color="blue">based on</font> our <font color="blue">discoveries depends upon</font> our ability to <font color="blue">enter into</font> <font color="blue">development</font>     and <font color="blue">licensing <font color="blue">arrangements</font></font></td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">enter into</font> advantageous licensing     or <font color="blue">development</font> <font color="blue">agreement</font>s will depend upon whether or not companies that     have <font color="blue">technology</font> complimentary to ours are willing or able to <font color="blue">enter into</font> an     <font color="blue">agreement</font>  with  us,  and on our <font color="blue">financial resources allocated</font> to such     <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>We also may have to rely on our <font color="blue">collaborators</font> and licensees or     <font color="blue">licensors</font>  for  marketing of services, or <font color="blue">distribution</font> of products and     services</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">enter into</font> such <font color="blue">development</font> and licensing     <font color="blue">arrangements</font>  or  implement  our strategy to develop and <font color="blue">commercialize</font>     <font color="blue">additional</font> products and services, it would have a material adverse effect on     our  results  of  operation  and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">enter into</font>     <font color="blue">collaborations</font> or <font color="blue">licensing <font color="blue">arrangements</font></font>, we may be forced to <font color="blue">relinquish</font>     rights to certain of our <font color="blue">technologies</font> or products, or <font color="blue">grant licenses</font> to     <font color="blue"><font color="blue">third parties</font> on terms</font> that are unfavorable to us</td>
    </tr>
    <tr>
      <td>If our patent <font color="blue">application</font>s do not result in <font color="blue">issued patents</font>, our <font color="blue">competitors</font>     may obtain rights to <font color="blue">commercialize</font> our discoveries, <font color="blue">which would</font> harm our     <font color="blue">competitive position</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font>, in part, on our ability to obtain <font color="blue">patent protection</font>     on our <font color="blue">proprietary</font> <font color="blue">technologies</font>, products and services and to <font color="blue">enforce such</font>     protection</td>
    </tr>
    <tr>
      <td>We may not be able to obtain <font color="blue">new patents</font> for these <font color="blue">technologies</font>,     products and services</td>
    </tr>
    <tr>
      <td>We also may not have the resources to <font color="blue">aggressively</font>     protect and enforce existing <font color="blue">patent protection</font></td>
    </tr>
    <tr>
      <td>We may need to obtain a     <font color="blue">license from certain <font color="blue">third parties</font> with respect</font> to any <font color="blue">patent covering</font>     <font color="blue">technologies</font> or <font color="blue">methodologies which</font> we wish to <font color="blue">incorporate into</font> our service     offerings,  but  we  may not be able to acquire <font color="blue">such licenses on terms</font>     acceptable to us, if at all</td>
    </tr>
    <tr>
      <td>17     ______________________________________________________________________    [41]Table of <font color="blue">Contents       </font>The scope of our <font color="blue">issued patents</font> may not <font color="blue">provide us with adequate protection</font>     of our <font color="blue"><font color="blue">intellectual</font> property</font>, <font color="blue">which would</font> harm our <font color="blue">competitive position</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">issued patents</font> that cover our <font color="blue">proprietary</font> <font color="blue">technologies</font> may not provide     us with substantial protection or be <font color="blue">commercially <font color="blue">beneficial</font></font> to us</td>
    </tr>
    <tr>
      <td>The     issuance of a <font color="blue">patent may</font> be <font color="blue">challenged with respect</font> to its validity or its     <font color="blue">enforceability</font></td>
    </tr>
    <tr>
      <td>The  US  Patent  and  <font color="blue">Trademark Office </font>(or a court of     <font color="blue"><font color="blue">appropriate</font> jurisdiction</font>), or any one of a number of <font color="blue">foreign patent offices</font>     where we have pursued <font color="blue">patent protection</font> may invalidate one or more of our     patents</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">third parties</font> may have patents of their own which     could, if asserted, <font color="blue">prevent us from practicing</font> our <font color="blue">proprietary</font> <font color="blue">technologies</font>,     including the methods we use to conduct <font color="blue">genotyping</font></td>
    </tr>
    <tr>
      <td>If we are otherwise     unable  to  practice  our patented <font color="blue">technologies</font>, we may not be able to     <font color="blue">commercialize</font>  our  <font color="blue">technologies</font> or services and our <font color="blue">competitors</font> could     <font color="blue">commercialize</font> our <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We currently believe that there may be at     <font color="blue">least one company actively infringing</font> our <font color="blue"><font color="blue">proprietary</font> single base primer</font>     extension <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>However, we have not completed an analysis of this     third party’s practices or of the practices of any other <font color="blue">third parties</font> and     cannot form a <font color="blue">conclusion at</font> this time as to <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td>We may need to initiate lawsuits to protect or enforce our patents and other     <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font>, <font color="blue">which could</font> result in the <font color="blue">forfeiture</font> of these     rights</td>
    </tr>
    <tr>
      <td>In order to protect or enforce our <font color="blue">patent rights</font>, we may need to initiate     patent <font color="blue">litigation</font> against <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">lawsuits could</font> be expensive,     take <font color="blue">significant</font> time and could divert <font color="blue">management</font>’s attention from other     business concerns</td>
    </tr>
    <tr>
      <td>These <font color="blue">lawsuits could</font> result in the in<font color="blue">validation</font> or a     <font color="blue">limitation</font>  in  the  scope  of our patents or <font color="blue">forfeiture</font> of the rights     <font color="blue">associated with</font> our patents</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we <font color="blue">will prevail</font> in     any future <font color="blue">litigation</font> or that a <font color="blue">court will</font> not <font color="blue">find damages</font> or award other     remedies in favor of the <font color="blue">opposing party</font> in any of these suits</td>
    </tr>
    <tr>
      <td>During the     course of these suits, there may be public <font color="blue">announcements</font> of the results of     hearings, motions and other <font color="blue">interim proceedings</font> or <font color="blue">development</font>s in the     <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td><font color="blue">Securities  </font>analysts  or  investors  may  perceive  these     <font color="blue">announcements</font> to be negative, <font color="blue">which would</font> likely cause the <font color="blue">market price</font> of     our stock to decline</td>
    </tr>
    <tr>
      <td>Other rights and measures that we rely upon to protect our <font color="blue">intellectual</font>     <font color="blue">property may</font> not be adequate to protect our products and services and could     reduce our ability to compete in the market</td>
    </tr>
    <tr>
      <td>In addition to patents, we rely on a <font color="blue">combination</font> of <font color="blue">trade secrets</font>, copyright     and  trademark  laws,  non-disclosure <font color="blue">agreement</font>s and other <font color="blue">contractual</font>     provisions and <font color="blue">technical measures</font> to protect our <font color="blue"><font color="blue">intellectual</font> property</font>     rights</td>
    </tr>
    <tr>
      <td>While we require employees, <font color="blue">collaborators</font>, consultants and other     <font color="blue">third parties</font> to <font color="blue">enter into</font> confidentiality and/or non-disclosure <font color="blue">agreement</font>s     where <font color="blue">appropriate</font>, any of the <font color="blue">following could still</font> occur:           •   the <font color="blue">agreement</font>s may be breached;           •   we may have inadequate remedies for any breach;           •   <font color="blue">proprietary</font> information could be disclosed to our <font color="blue">competitors</font>; or           •   <font color="blue">others may independently</font> develop <font color="blue">substantially</font> equivalent <font color="blue">proprietary</font>     information and <font color="blue">techniques</font> or <font color="blue">otherwise gain access</font> to our <font color="blue">trade secrets</font> or     disclose such <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>To our knowledge, we have <font color="blue">never been materially harmed by</font> a <font color="blue">breach under</font> any     of <font color="blue">circumstances listed</font> above</td>
    </tr>
    <tr>
      <td>However, if for any of the above reasons our     <font color="blue"><font color="blue">intellectual</font> property</font> is disclosed or mis<font color="blue">appropriate</font>d, it <font color="blue">would harm both</font>     our ability to protect our rights and our <font color="blue">competitive position</font></td>
    </tr>
    <tr>
      <td>The pursuit     of a remedy for such an alleged <font color="blue">breach may cost <font color="blue">substantially</font></font> in terms of     the time, effort and expenses of our resources</td>
    </tr>
    <tr>
      <td>Our ability to utilize our net operating <font color="blue">loss <font color="blue">carryforwards</font> may</font> be limited</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, our net operating loss, or NOL, <font color="blue">carryforwards</font> were     <font color="blue">approximately</font> dlra234 million and <font color="blue">approximately</font> dlra194 million for Federal and     state  income  tax  purposes,  <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td><font color="blue">Our Federal </font>and state NOL     <font color="blue">carryforwards</font> begin to expire in 2006</td>
    </tr>
    <tr>
      <td><font color="blue">Utilization </font>of our NOLs to offset     future taxable income, if any,                                           18     ______________________________________________________________________    [42]Table of <font color="blue">Contents       </font>may be <font color="blue">substantially</font> limited due to “change of ownership” provisions in the     <font color="blue">Tax Reform Act </font>of 1986, or the Act</td>
    </tr>
    <tr>
      <td>The Act provides for a <font color="blue">limitation</font> on the     annual  use  of NOL <font color="blue">carryforwards</font> and research and <font color="blue">development</font> credits     <font color="blue">following certain ownership</font> changes, <font color="blue">as <font color="blue">defined by</font></font> the Act, <font color="blue">which could</font>     <font color="blue"><font color="blue">significant</font>ly</font> limit our ability to utilize these <font color="blue">carryforwards</font> and research     and <font color="blue">development</font> credits</td>
    </tr>
    <tr>
      <td>We have determined that an ownership change, as     <font color="blue">defined by</font> the Act, occurred in 1999</td>
    </tr>
    <tr>
      <td><font color="blue">Approximately </font>dlra36 million of NOL     <font color="blue">carryforwards</font> is limited due to this ownership change</td>
    </tr>
    <tr>
      <td>Additionally, because     US <font color="blue">tax laws limit</font> the time <font color="blue">during which</font> these <font color="blue">carryforwards</font> may be applied     <font color="blue">against future taxes</font>, we may not be able to take full advantage of these     <font color="blue">attributes</font> for Federal <font color="blue">income tax purposes</font></td>
    </tr>
    <tr>
      <td>The NOL <font color="blue">carryforwards</font> subject to     <font color="blue">expiration through</font> the year 2019 is <font color="blue">approximately</font> dlra32 million</td>
    </tr>
    <tr>
      <td>We may have     experienced other ownership changes, <font color="blue">as <font color="blue">defined by</font></font> the Act, as a result of     past  <font color="blue">financings</font>  and  may experience others in <font color="blue">connection with</font> future     <font color="blue">financings</font></td>
    </tr>
    <tr>
      <td>Accordingly, our ability to utilize the <font color="blue">aforementioned</font> Federal     NOL <font color="blue">carryforwards</font> may be further limited in the future</td>
    </tr>
    <tr>
      <td><font color="blue">Risks Associated </font>with Our Common Stock          Future issuance of our <font color="blue">securities may dilute</font> the rights of our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td><font color="blue">Our <font color="blue">Board of Directors </font></font>has the authority to <font color="blue">issue shares</font> of <font color="blue">preferred stock</font>     and to determine the price, <font color="blue">preferences</font>, privileges and other terms of these     shares</td>
    </tr>
    <tr>
      <td><font color="blue">Our <font color="blue">Board of Directors </font></font><font color="blue">may exercise</font> this <font color="blue">authority without</font> any     <font color="blue">further approval</font> of our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Additionally, if we need to raise     <font color="blue">additional</font>  funds  through  the  sale  of  equity, convertible debt or     equity-linked securities, your <font color="blue">percentage ownership</font> in the Company on a     <font color="blue">diluted basis will</font> be reduced</td>
    </tr>
    <tr>
      <td>These <font color="blue">transactions may dilute</font> the value of     our outstanding <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may also issue securities</font> that have rights,     <font color="blue">preferences</font> and <font color="blue">privileges senior</font> to our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We  have <font color="blue">various mechanisms</font> in place that you as a <font color="blue">stockholder may</font> not     consider favorable, <font color="blue">which may discourage takeover attempts</font> and <font color="blue">may prevent</font>     or frustrate attempts by <font color="blue">stockholders</font> to change our direction or <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>Certain provisions of our <font color="blue">certificate</font> of <font color="blue">incorporation</font> and by-laws, as well     as Section 203 of the <font color="blue">Delaware General Corporation Law </font>and our adoption of a     shareholder’s rights plan, may discourage, delay or prevent a change in     control  or  the  ability  of  <font color="blue">stockholders</font> to change our direction or     <font color="blue">management</font>, even if the changes would be <font color="blue">beneficial</font> to <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>provisions include:           •   <font color="blue">authorizing</font> the issuance of “blank check” <font color="blue">preferred stock</font> that could     be designated and issued by our <font color="blue">Board of Directors </font>to increase the number of     outstanding shares and thwart a takeover attempt;           •   creating a classified board of <font color="blue">directors</font> with staggered, three-year     terms, which may lengthen the time required to gain control of our Board of     Directors;           •   <font color="blue">prohibiting cumulative voting</font> in the election of <font color="blue">directors</font>, which will     allow a majority of <font color="blue">stockholders</font> to control the election of all <font color="blue">directors</font>;           •   requiring super-majority voting to effect <font color="blue">certain amendments</font> to our     <font color="blue">certificate</font> of <font color="blue">incorporation</font> and by-laws;           •   limiting who <font color="blue">may call special meetings</font> of <font color="blue">stockholders</font>;           •   prohibiting stockholder action by written consent, which requires all     actions to be taken at a meeting of <font color="blue">stockholders</font>; and           •   <font color="blue">establishing advance</font> notice <font color="blue">requirements</font> for <font color="blue">nominations</font> of candidates     for election to our <font color="blue">Board of Directors </font>or for <font color="blue">proposing matters</font> that can be     acted upon by <font color="blue">stockholders</font> at stockholder meetings</td>
    </tr>
    <tr>
      <td>In addition, pursuant to our <font color="blue">stockholder rights</font> plan, each share of our     <font color="blue">common stock</font> has an <font color="blue">associated preferred</font> share purchase right</td>
    </tr>
    <tr>
      <td>The rights     will not <font color="blue">trade separately from</font> the <font color="blue">common stock</font> until, and are exercisable     only upon, the <font color="blue">acquisition</font> or the potential <font color="blue">acquisition</font> through tender offer     by a person or group of 15prca or more of our outstanding <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>19     ______________________________________________________________________    [43]Table of <font color="blue">Contents       </font>Our <font color="blue">common stock</font> may be <font color="blue">delisted from</font> <font color="blue">The Nasdaq National Market</font></td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>of material <font color="blue">weaknesses</font> in our <font color="blue">internal control</font> <font color="blue">over financial</font>     reporting and the <font color="blue">restatement</font> of our <font color="blue">consolidated</font> <font color="blue">financial statements</font> for     the quarters ended June 30, 2005 and <font color="blue">September </font>30, 2005, we did not file     this <font color="blue">Annual Report </font>on Form 10-K in a <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>As a result, The Nasdaq     National Market, or Nasdaq, notified us that we were not in <font color="blue">compliance with</font>     a listing standard of Nasdaq</td>
    </tr>
    <tr>
      <td>We <font color="blue">subsequently submitted</font> a request for a     Nasdaq Listing Qualifications Panel, or the Panel, to consider our continued     listing</td>
    </tr>
    <tr>
      <td>The hearing was held April 27, 2006, and as of the filing of this     Annual  Report  on Form 10-K, the Panel had yet to render its decision     regarding the <font color="blue">continued listing</font> of our <font color="blue">common stock</font> on Nasdaq</td>
    </tr>
    <tr>
      <td>In addition,     as a result of the delay in filing this <font color="blue">Annual Report </font>on Form 10-K, we did     not file our <font color="blue">Quarterly Report </font>on Form 10-Q for the quarter ended March 31,     2006 by the date required by the <font color="blue">SEC On May </font>16, 2006, we received a letter     from Nasdaq indicating that the failure to file our <font color="blue">Quarterly Report </font>on <font color="blue">Form     </font>10-Q for the quarter ended March 31, 2006 serves as an <font color="blue">additional</font> basis for     delisting our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">If the Panel </font>rules against us or if we fail to demonstrate <font color="blue">compliance with</font>     applicable Nasdaq rules in the future, our <font color="blue">common stock</font> may be <font color="blue">delisted from</font>     Nasdaq,  <font color="blue">which could</font> materially <font color="blue"><font color="blue">adversely</font> affect</font> the <font color="blue">trading price</font> and     volumes of our <font color="blue">common stock</font> regardless of our actual results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Public <font color="blue">announcements</font> regarding the <font color="blue">possible delisting</font> of     our <font color="blue">common stock</font> could result in <font color="blue">extreme price</font> and <font color="blue">volume <font color="blue">fluctuations</font></font> that     are unrelated or <font color="blue">disproportionate</font> to our actual operating performance</td>
    </tr>
    <tr>
      <td>In     addition, the delisting of our <font color="blue">common stock</font> would impair the liquidity of     our <font color="blue">common stock</font> and there is no assurance that a <font color="blue">market would</font> exist for our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Even though we have filed this <font color="blue">Annual Report </font>on Form 10-K and     expect to file our <font color="blue">Quarterly Report </font>on Form 10-Q for the quarter ended     March 31, 2006 as soon as possible, we <font color="blue">cannot assure</font> you that the Panel will     not determine to delist our <font color="blue">common stock</font> from Nasdaq</td>
    </tr>
    <tr>
      <td>Our stock price has been, and <font color="blue">likely will continue</font> to be, volatile and your     <font color="blue">investment</font> may suffer a decline in value</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font>s for securities of <font color="blue">companies quoted on</font> The Nasdaq Stock     Market, including our <font color="blue">market price</font>, have in the past been, and are likely to     continue in the future to be, very volatile</td>
    </tr>
    <tr>
      <td><font color="blue">Between January </font>1, 2004 and     <font color="blue">December </font>31, 2005, the closing price of our <font color="blue">common stock</font> (adjusted for our     <font color="blue">reverse stock split on</font> March 31, 2004) ranged from a low of dlra5dtta46 to a high     of dlra14dtta25</td>
    </tr>
    <tr>
      <td><font color="blue">The Nasdaq Composite Index </font>has <font color="blue"><font color="blue">significant</font>ly</font> declined since our     <font color="blue">initial public offering</font> in May 2000 and remains very volatile</td>
    </tr>
    <tr>
      <td>The market     price of our <font color="blue">common stock</font> has been, and <font color="blue">likely will continue</font> to be, subject     to substantial <font color="blue">volatility depending upon</font> many factors, many of which are     beyond our control, including:           •   <font color="blue">announcements</font> regarding the results of <font color="blue">development</font> efforts by us or     our <font color="blue">competitors</font>;           •   <font color="blue">announcements</font> regarding the <font color="blue">acquisition</font> of <font color="blue">technologies</font> or companies     by us or our <font color="blue">competitors</font>;           •   changes in our existing <font color="blue">development</font> or <font color="blue">licensing <font color="blue">arrangements</font></font> or     formation of new <font color="blue">development</font> or <font color="blue">licensing <font color="blue">arrangements</font></font>;           •   <font color="blue">technological innovations</font> or new <font color="blue">service offerings</font> developed by us or     our <font color="blue">competitors</font>;           •   changes in our <font color="blue"><font color="blue">intellectual</font> property</font> portfolio;           •   <font color="blue">development</font>s or <font color="blue">disputes concerning</font> our <font color="blue">proprietary</font> rights;           •   issuance of new or changed <font color="blue">securities analysts</font>’ reports and/or     <font color="blue">recommendations applicable</font> to us;           •   <font color="blue">additions</font> or <font color="blue">departures</font> of our <font color="blue">key personnel</font>;           •   our operating losses; and           •   <font color="blue">continued economic uncertainty with respect</font> to the valuation of     certain <font color="blue">technology</font> companies and other <font color="blue">market conditions</font></td>
    </tr>
    <tr>
      <td>20     ______________________________________________________________________    [44]Table of <font color="blue">Contents       </font>Fluctuations in our quarterly revenues and operating results may <font color="blue">negatively</font>     impact our stock price</td>
    </tr>
    <tr>
      <td>Our revenues and results of <font color="blue">operations</font> have fluctuated <font color="blue"><font color="blue">significant</font>ly</font> in the     past and these <font color="blue">fluctuations</font> are likely to continue in the future due to a     variety of factors, many of which are outside of our control</td>
    </tr>
    <tr>
      <td>These factors     include:           •   the timing of US Federal funding for forensic DNA <font color="blue">testing through</font> the     NIJ;           •   our ability to secure new <font color="blue">contractual</font> <font color="blue">relationship</font>s for forensic,     family <font color="blue">relationship</font> and animal and <font color="blue">agricultural testing</font> or retain existing     <font color="blue">relationship</font>s upon contract expirations;           •   the volume and timing of <font color="blue">testing samples</font> received in our <font color="blue">laboratories</font>     for <font color="blue">testing services</font>;           •   the number of trained DNA <font color="blue">analysts which</font> are available to process the     samples for <font color="blue">testing services</font>;           •   the number, timing and significance of <font color="blue">new services introduced by</font> our     <font color="blue">competitors</font>;           •   our ability to develop, market and <font color="blue">introduce new services on</font> a timely     basis;           •   our ability to maintain and grow the volume of <font color="blue">forensic testing</font>     services in the UK, <font color="blue">either through extension</font> of our <font color="blue">agreement</font> with FAL or by     directly providing our services to UK <font color="blue">police forces</font>;           •   changes in the cost, quality and <font color="blue">availability</font> of <font color="blue"><font color="blue">intellectual</font> property</font>     and <font color="blue">components</font> required to perform our services;           •   <font color="blue">availability</font> of commercial and <font color="blue">government funding</font> to <font color="blue">researchers</font> who     use our services; and           •   the <font color="blue">inherent seasonality</font> in our <font color="blue">animal testing</font> business during the     <font color="blue">winter months</font></td>
    </tr>
    <tr>
      <td>Fixed operating costs <font color="blue">associated with</font> our <font color="blue">technologies</font> and services, as well     as personnel costs, marketing and <font color="blue">sales programs</font> and overhead costs, account     for a substantial portion of our operating expenses</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot adjust</font> these     <font color="blue">expenses quickly</font> in the short term</td>
    </tr>
    <tr>
      <td>If our <font color="blue">testing volumes</font> and related     <font color="blue">pricing decline due</font> to <font color="blue">market pressure</font>, our <font color="blue">revenues will decline</font> and we may     not  be able to reduce our operating <font color="blue">expenses accordingly</font></td>
    </tr>
    <tr>
      <td>Our loss of     revenues and failure to reduce operating <font color="blue">expenses could harm</font> our operating     results  for a <font color="blue">particular fiscal period</font></td>
    </tr>
    <tr>
      <td>In addition, market and other     <font color="blue">conditions may</font> require certain non-cash charges such as impairment charges     related to long-lived assets and <font color="blue">restructuring charges</font> to be <font color="blue">recorded by us</font>     in <font color="blue">future periods</font></td>
    </tr>
    <tr>
      <td>If our operating results in any quarter or <font color="blue">quarters fail</font>     to meet the <font color="blue">expectations</font> of <font color="blue"><font color="blue">public market</font> analysts</font> or investors, the market     price of our <font color="blue">common stock</font> is likely to fall</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that your <font color="blue">investment</font> in our <font color="blue">common stock</font> will not     fluctuate <font color="blue"><font color="blue">significant</font>ly</font></td>
    </tr>
    <tr>
      <td>One or more of these factors could <font color="blue"><font color="blue">significant</font>ly</font>     harm our business and cause a decline in the price of our <font color="blue">common stock</font> in     the <font color="blue">public market</font></td>
    </tr>
  </tbody>
</table>